16 September 2025 ORYZON strengthens patent portfolio for iadademstat and vafidemstat with new Decisions to Grant
25 August 2025 ORYZON receives European Medicines Agency approval to initiate a Phase Ib study of iadademstat in sickle cell disease
30 July 2025 ORYZON reports financial results and corporate update for half-year ending June 30, 2025
9 July 2025 Oryzon Virtual KOL Event to discuss the unmet medical need in Borderline Personality Disorder and the design of vafidemstat’s Phase III PORTICO-2 trial